Arrow Therapeutics selects a further Hepatitis C compound A-689
Arrow Therapeutics has announced that a further hepatitis C compound, A-689, has entered full preclinical development. A-689 is the second compound from Arrow's broad approach to the NS5a target to enter development. November 2006 saw Arrow's first Hepatitis C compound, A-831, enter Phase I trials. Both compounds target the novel NS5a protein but have completely different chemical structures and bind to the target at different sites.
Once again A-689 originates from Arrow's focused chemical library and was optimised inhouse. According to the company, the compound has shown highly potent activity in the replicon assay and has an excellent therapeutic index and good pharmacokinetic properties. Phase I trials on A-689 are planned for the second half of 2007.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.